US regulators sent seemingly mixed messages this month about the outlook for animal-derived, or desiccated, thyroid medicines ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...

Over the past decade, AbbVie's shares have increased by 353.3%, or 16.3% annually, with dividends reinvested. That's ...

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie.

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

AbbVie (ABBV) announced a $195 million investment in its North Chicago manufacturing facility to boost domestic API ...

Sales of rhCollagen and bioinks primed for augmentation following new U.S.-based commercial executive hire -- Raised $3.6 million in registered direct offering in second quarter - REHOVOT ...

AbbVie has announced a USD 195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic ...

UChicago Medicine is launching a national cancer network to bring its academic medicine expertise to other communities in the ...

ICICI Securities is bearish on Glenmark Pharmaceuticals has recommended sell rating on the stock with a target price of Rs 1570 in its research report dated August 19, 2025.